IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution

BACKGROUND: Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing. Reports of IDH1/2‐mutated non–small cell lung cancers (NSCLCs), however, are limited. METHODS: We eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Erika F., De Marchi, Federico, Lokhandwala, Parvez M., Belchis, Deborah, Xian, Rena, Gocke, Christopher D., Eshleman, James R., Illei, Peter, Li, Ming‐Tseh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Cancer Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300411/
https://www.ncbi.nlm.nih.gov/pubmed/32333643
http://dx.doi.org/10.1002/cam4.3058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300411/
https://www.ncbi.nlm.nih.gov/pubmed/32333643
http://dx.doi.org/10.1002/cam4.3058

Ejemplares similares